A new approach of macrophage checkpoint blockade produces responses in half of patients with relapsed or refractory aggressive lymphoma, early research shows. The combination of a novel anti-cancer antibody known as 5F9 (Hu5F9-G4) with rituximab, induced a positive response in 11 out of 22 people with relapsed/refractory non-Hodgkin’s lymphoma, according to results of a Phase 1b ...
Macrophage checkpoint blockade shows promise in refractory lymphoma
By Michael Woodhead
7 Nov 2018